Ken Griffin Ani Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ani Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 569,630 shares of ANIP stock, worth $50.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

569,630

Previous 2,000 28381.5%

Holding current value

$50.3 Million

Previous $133,000 27845.86%

% of portfolio

0.01%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$57.79 - $72.95 $8.88 Million - $11.2 Million	-153,699 Reduced 21.25%	569,630 $37.2 Million
Q1 2025 May 15, 2025	BUY	$53.93 - $68.36 $7.1 Million - $9.01 Million	131,735 Added 22.27%	723,329 $48.4 Million
Q4 2024 Feb 14, 2025	BUY	$53.35 - $61.74 $3.29 Million - $3.81 Million	61,717 Added 11.65%	591,594 $32.7 Million
Q3 2024 Nov 14, 2024	BUY	$54.33 - $65.72 $8.78 Million - $10.6 Million	161,538 Added 43.86%	529,877 $31.6 Million
Q2 2024 Aug 14, 2024	BUY	$58.53 - $68.82 $14.6 Million - $17.2 Million	249,573 Added 210.14%	368,339 $23.5 Million
Q1 2024 May 15, 2024	SELL	$54.2 - $69.69 $2.99 Million - $3.85 Million	-55,230 Reduced 31.74%	118,766 $8.21 Million
Q4 2023 Feb 14, 2024	BUY	$48.72 - $65.43 $6.1 Million - $8.19 Million	125,166 Added 256.33%	173,996 $9.59 Million
Q3 2023 Nov 14, 2023	BUY	$50.28 - $64.61 $128,063 - $164,561	2,547 Added 5.5%	48,830 $2.84 Million
Q2 2023 Aug 14, 2023	BUY	$37.29 - $53.83 $1.71 Million - $2.47 Million	45,915 Added 12476.9%	46,283 $2.49 Million
Q1 2023 May 15, 2023	BUY	$37.61 - $45.72 $1,692 - $2,057	45 Added 13.93%	368 $14,000
Q4 2022 Feb 14, 2023	SELL	$31.9 - $41.95 $272,043 - $357,749	-8,528 Reduced 96.35%	323 $12,000
Q3 2022 Nov 14, 2022	SELL	$29.83 - $38.01 $1.89 Million - $2.41 Million	-63,365 Reduced 87.74%	8,851 $284,000
Q2 2022 Aug 15, 2022	BUY	$23.09 - $33.46 $1.48 Million - $2.15 Million	64,228 Added 804.06%	72,216 $2.14 Million
Q1 2022 May 16, 2022	SELL	$26.91 - $47.15 $407,363 - $713,756	-15,138 Reduced 65.46%	7,988 $224,000
Q4 2021 Feb 14, 2022	SELL	$32.97 - $56.85 $311,896 - $537,801	-9,460 Reduced 29.03%	23,126 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$26.48 - $35.99 $143,601 - $195,173	-5,423 Reduced 14.27%	32,586 $1.07 Million
Q2 2021 Aug 16, 2021	SELL	$31.86 - $38.6 $360,018 - $436,180	-11,300 Reduced 22.92%	38,009 $1.33 Million
Q1 2021 May 17, 2021	SELL	$28.4 - $36.14 $526,195 - $669,601	-18,528 Reduced 27.31%	49,309 $1.78 Million
Q4 2020 Feb 16, 2021	BUY	$23.69 - $31.47 $846,988 - $1.13 Million	35,753 Added 111.44%	67,837 $1.97 Million
Q3 2020 Nov 16, 2020	BUY	$26.38 - $33.1 $846,375 - $1.06 Million	32,084 New	32,084 $905,000
Q2 2020 Aug 14, 2020	SELL	$29.93 - $50.1 $268,053 - $448,695	-8,956 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$30.35 - $67.14 $14,901 - $32,965	491 Added 5.8%	8,956 $365,000
Q4 2019 Feb 14, 2020	BUY	$55.65 - $79.83 $108,239 - $155,269	1,945 Added 29.83%	8,465 $522,000
Q2 2019 Aug 14, 2019	SELL	$67.77 - $82.2 $354,098 - $429,495	-5,225 Reduced 44.49%	6,520 $536,000
Q1 2019 May 15, 2019	SELL	$45.83 - $70.54 $113,475 - $174,657	-2,476 Reduced 17.41%	11,745 $0
Q4 2018 Feb 14, 2019	BUY	$41.17 - $56.44 $190,781 - $261,542	4,634 Added 48.34%	14,221 $640,000
Q3 2018 Nov 13, 2018	BUY	$52.95 - $71.34 $248,017 - $334,156	4,684 Added 95.53%	9,587 $0
Q1 2018 May 11, 2018	SELL	$56.98 - $72.41 $107,749 - $136,927	-1,891 Reduced 27.83%	4,903 $285,000
Q4 2017 Feb 09, 2018	SELL	$53.3 - $74.56 $79,097 - $110,647	-1,484 Reduced 17.93%	6,794 $438,000
Q3 2017 Nov 09, 2017	BUY	$43.46 - $52.49 $359,761 - $434,512	8,278	8,278 $435,000

Others Institutions Holding ANIP

# of Institutions

242

Shares Held

20M

Call Options Held

19.9K

Put Options Held

12.8K

View Full List

About ANI PHARMACEUTICALS INC

Ticker ANIP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 17,426,000
Market Cap $1.54B
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...

More about ANIP

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account